This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DURECT Completes Enrollment In Pivotal U.S. Phase III Trial For POSIDUR® (BESST)

CUPERTINO, Calif., Sept. 6, 2011 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today the dosing of the last patient in the U.S. pivotal Phase III clinical study for POSIDUR® known as BESST (Bupivacaine Effectiveness and Safety in SABER trial).  POSIDUR is a post-operative pain relief depot that utilizes DURECT's patented SABER™ technology to deliver bupivacaine to provide up to three days of pain relief after surgery.  DURECT expects to report top-line data from the BESST trial in the fourth quarter of 2011 and, if the data are positive, to submit the New Drug Application in the first half of 2012.

(Logo: http://photos.prnewswire.com/prnh/20020717/DRRXLOGO)

"We believe that POSIDUR has the potential to play a major role in treating post-surgical pain, reducing the need for systemic narcotics and associated side effects, as well as costs associated with extended hospital stays," stated James E. Brown, President and CEO.

"We are encouraged by this important development milestone for POSIDUR, an innovative product candidate which may represent a significant step-forward in the management of acute pain for patients following surgical procedures. Hospira is committed to bringing POSIDUR to market rapidly following FDA review and approval," added Andrew Robbins, Vice President, corporate development at Hospira, Inc. POSIDUR is licensed to Hospira (NYSE: HSP) for commercialization in the U.S. and Canada.

About the Design of BESST

BESST is an international, multi-center, randomized, double-blind, controlled trial evaluating the safety, efficacy, effectiveness, and pharmacokinetics of POSIDUR in 305 patients undergoing a variety of general abdominal surgical procedures.   Eligible patients were randomly assigned to one of three cohorts:

Cohort 1: An active comparator cohort in which 48 patients were randomized to receive either POSIDUR 5.0 mL or commercially available Bupivacaine HCl  solution after laparotomy.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs